Simvastatin Tablet, Film Coated
Product Images NDC 71610-609

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 71610-609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 40 mg (71610 0609 45)

Bottle Label 40 mg (71610 0609 45)
FDA Label Image

Bottle Label 40 mg (71610 0610 45)

Bottle Label 40 mg (71610 0610 45)
FDA Label Image

Bottle Label 80 mg (71610 0611 45)

Bottle Label 80 mg (71610 0611 45)
Not available. The given text seems to be an incorrect output.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

Footnote For Table 3 (Footnote For Table 3)
This text provides information on the results of a chemical assay, and the potential inhibitors that could affect CYP3A4. It also clarifies that "Simvastatin acid" refers to the p-hydroxyacid of simvastatin. However, there is a lack of information on the effect of grapefruit juice on simvastatin pharmacokinetics. The text provides details about the administration of grapefruit juice in double-strength and single-strength doses, along with simvastatin.*
FDA Label Image

Figure 9 (Simvastatin 10)

Figure 9 (Simvastatin 10)
FDA Label Image

Table2 (Simvastatin 2)

Table2 (Simvastatin 2)
FDA Label Image

Structure (Simvastatin 3)

Structure (Simvastatin 3)
FDA Label Image

Table 3 (Simvastatin 4)

Table 3 (Simvastatin 4)
Not available.*
FDA Label Image

Table 4 (Simvastatin 5)

Table 4 (Simvastatin 5)
FDA Label Image

Figure 5 (Simvastatin 6)

Figure 5 (Simvastatin 6)
FDA Label Image

Figure 6 (Simvastatin 7)

Figure 6 (Simvastatin 7)
FDA Label Image

Figure 7 (Simvastatin 8)

Figure 7 (Simvastatin 8)
FDA Label Image

Figure 8 (Simvastatin 9)

Figure 8 (Simvastatin 9)
FDA Label Image

Table 1 (Table1)

Table 1 (Table1)
This is a list of drug interactions associated with increased risk of myopathy/rhabdomyolysis. The list includes prescribing recommendations for interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, and other medications. Simvastatin, a cholesterol-lowering medication, should not be taken with certain medications such as verapamil, diltiazem, and amiodarone, unless under specific prescribing recommendations. Additionally, niacin should not be taken with simvastatin while for patients with HOFH, Lomitapide should not be used. There is an instruction to avoid grapefruit juice as well.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.